ABSTRAL delivers fast relief for more pain-free minutes1-3

Despite adequate treatment of persistent cancer pain, over 50% of patients still suffer from BTcP.4 See how ABSTRAL® (fentanyl) sublingual tablets work differently to help deliver fast relief of BTcP.1-3

 
 

Register now to receive updates and exclusive information
about ABSTRAL and Galena Biopharma, Inc.

REGISTER NOW

References

  1. ABSTRAL [package insert]. Lake Oswego, OR: Galena Biopharma Inc; 2013.
  2. Chrvala CA, Caspi A. Abstral (fentanyl sublingual tablets for breakthrough cancer pain). P&T Product Profiler. 2011;36(2):2-28. 
  3. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25(12):2877-2885.
  4. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437-1449.
  5. TIRF REMS Access program Web site. https://www.tirfremsaccess.com/TirfUI/rems/home.action. Accessed August 18, 2013.